In addition, survival analyses demonstrated that higher MCAM expression was significantly associated with worse prognosis in patients with brain low‐grade glioma (HR = 2.2, adjusted p‐value <0.05) and mesothelioma (HR = 2.8, adjusted p‐value <0.05) compared to other patients. Here, MCAM is linked to mesothelioma.